What causes sjogrens

What It Is

Sjögren's syndrome is a chronic autoimmune disorder where the immune system attacks the glands responsible for producing saliva and tears, resulting in dry mouth (xerostomia) and dry eyes (keratoconjunctivitis sicca). This systemic disease can affect multiple organ systems including the lungs, kidneys, nerves, and blood vessels beyond the primary glandular dysfunction. Named after Swedish ophthalmologist Henrik Sjögren who first described it in 1933, the syndrome occurs when B-lymphocytes and T-lymphocytes infiltrate and destroy the salivary and lacrimal glands. It is classified as either primary Sjögren's (occurring alone) or secondary Sjögren's (occurring with other autoimmune diseases like rheumatoid arthritis or lupus).

Henrik Sjögren published his initial clinical observations in 1933 describing a triad of keratoconjunctivitis sicca, xerostomia, and arthritis in a cohort of women. Throughout the 1950s and 1960s, researchers began isolating and characterizing autoantibodies specific to Sjögren's syndrome. In 1968, researchers discovered the anti-SSA/Ro (Sjögren's syndrome antigen A) and anti-SSB/La (Sjögren's syndrome antigen B) antibodies, providing objective diagnostic markers. The classification criteria were formally established by international consensus in 2002, and updated in 2016 to improve early diagnosis and disease recognition.

Sjögren's syndrome is classified into primary and secondary forms based on the presence of other autoimmune diseases. Primary Sjögren's presents with glandular dysfunction and systemic manifestations without concurrent autoimmune disease, affecting approximately 50-60% of Sjögren's patients. Secondary Sjögren's occurs with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), or scleroderma, affecting 40-50% of patients with these conditions. Additional classification includes serological subtypes based on antibody presence: anti-SSA/SSB positive (60-70% of patients), anti-SSA/SSB negative (30-40%), and rheumatoid factor or ANA positivity.

How It Works

The pathophysiology of Sjögren's involves a multi-step autoimmune process beginning with genetic susceptibility (HLA-DR3, HLA-B8, HLA-DQ2) that predisposes immune dysregulation. Environmental triggers, particularly viral infections like Epstein-Barr virus (EBV), reactivate or establish persistent infection in salivary glands. The viral antigens cross-react with self-antigens on acinar and ductal cells through molecular mimicry, breaking immune tolerance. B-lymphocytes produce autoantibodies (anti-SSA/Ro and anti-SSB/La) while T-lymphocytes infiltrate glands, causing chronic inflammation and progressive gland destruction.

A real-world example involves a 45-year-old female patient (representative of typical primary Sjögren's) who develops persistent dry mouth despite normal salivary gland ultrasound initially. Mayo Clinic rheumatologists perform salivary gland biopsy revealing lymphocytic sialadenitis with focus score ≥1 (diagnostic criterion), confirming Sjögren's diagnosis. Blood tests show anti-SSB/La antibodies (present in 40-60% of primary Sjögren's), elevated RF (60-70% of cases), and positive ANA (60% of cases). Johns Hopkins Ophthalmology Department documents keratitis sicca and Schirmer test results <5 mm in 5 minutes (normal is >15 mm).

Practical implementation of disease understanding involves recognizing the inflammatory cascade: EBV or other viral infection → viral persistence in salivary tissue → B-cell activation → autoantibody production → T-cell infiltration → glandular destruction. In primary Sjögren's diagnosis, physicians perform specific testing: Schirmer test (measures tear production), lissamine green or rose Bengal staining (demonstrates corneal damage), unstimulated salivary flow rate testing (normal >1.5 mL/15 min), and salivary gland biopsy (shows lymphocytic infiltration). Disease activity monitoring uses the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (EULAR SSdi) to track progression. Treatment focuses on symptom management with artificial tears/saliva, cholinergic agonists (pilocarpine, cevimeline), and immunosuppression (methotrexate, rituximab) for systemic manifestations.

Why It Matters

Sjögren's syndrome affects an estimated 500,000 to 1 million Americans, with 90% of patients being women, representing one of the most common autoimmune diseases. The disease causes significant morbidity with up to 60% of patients reporting severe fatigue, reduced quality of life comparable to patients with diabetes or heart disease, and substantial healthcare costs exceeding $18,000 annually per patient. Dental complications including severe cavities, tooth loss, and oral infections occur in 80% of patients due to xerostomia. Early diagnosis and treatment can prevent serious complications, making understanding causation critical for patient outcomes.

Sjögren's syndrome carries important clinical implications across multiple specialties including rheumatology, ophthalmology, dentistry, and otolaryngology. The Stanford University School of Medicine and Mayo Clinic have established comprehensive Sjögren's programs recognizing systemic manifestations including interstitial lung disease (affecting 3-13% of patients), glomerulonephritis (affecting up to 25%), and peripheral neuropathy (affecting up to 70%). Rituximab (Rituxan), a B-cell depleting agent, was approved by the FDA in 2023 specifically for primary Sjögren's, representing the first approved biologic therapy and validating the B-cell-mediated pathophysiology. Early diagnosis through appropriate antibody testing (anti-SSA/SSB) and gland biopsy prevents years of misdiagnosis and organ damage.

Future developments in Sjögren's management include personalized medicine approaches targeting specific immune pathways based on serological subtypes. Research at Cambridge University and MIT is investigating chimeric antigen receptor (CAR) T-cell therapy to eliminate autoreactive B-lymphocytes while preserving normal immune function. Novel biomarkers including exosomal miRNAs are being developed for disease activity monitoring and treatment response prediction. Gene therapy approaches targeting HLA molecules and immune tolerance restoration are in preclinical development, potentially offering curative treatments within the next decade.

Common Misconceptions

A common misconception is that Sjögren's syndrome causes only dry eyes and mouth, but it is actually a systemic autoimmune disease affecting multiple organ systems. Patients often develop pulmonary involvement (interstitial lung disease), renal disease, peripheral neuropathy, and hematologic abnormalities (anemia, thrombocytopenia) in 40-60% of cases. Some patients experience severe systemic manifestations as their primary symptoms, with glandular dysfunction being secondary or mild. Delayed recognition of systemic disease leads many patients to be misdiagnosed with chronic fatigue syndrome or depression rather than treated for underlying autoimmune disease.

Another misconception is that Sjögren's syndrome primarily affects elderly patients, when in reality it can develop at any age including childhood. While the average age of primary Sjögren's diagnosis is 50 years, the actual disease often begins 5-10 years earlier but goes unrecognized. Pediatric-onset Sjögren's is rare but documented, and juvenile-onset secondary Sjögren's occurs in children with lupus or other autoimmune diseases. This misconception delays diagnosis in younger patients whose symptoms are often attributed to stress, allergies, or anxiety rather than investigated as potential autoimmune disease.

A third misconception is that Sjögren's syndrome is non-progressive and benign, but some patients develop serious complications including lymphoma, vasculitis, and end-stage renal disease. Primary Sjögren's patients have a 40-60 fold increased risk of developing non-Hodgkin lymphoma, particularly mucosa-associated lymphoid tissue (MALT) lymphoma of the parotid glands. Systemic complications including pulmonary fibrosis, glomerulonephritis, and neuropathy can cause permanent organ dysfunction. Without appropriate monitoring and immunosuppressive therapy, Sjögren's can progress to organ-threatening disease, making understanding its systemic nature critical for patient management.